Sector valuations VYNE Therapeutics Inc.
Equities
VYNE
US92941V3087
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3600 USD | -4.15% |
|
-3.69% | -89.25% |
| Nov. 06 | VYNE Therapeutics Q3 net loss narrows, strategic review ongoing | RE |
| Nov. 06 | VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 | CI |
Main competitors
| P/E (N) | Price to Book (N) | PEG (N) | EV / Sales (N) | EV / EBITDA (N) | EV / EBIT (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|
 | -0.52x | - | 0.02x | - | - | - | - | 11.98M | |
| 46.99x | 7.65x | 1.85x | 11.45x | 41.14x | 42.38x | -.--% | 52.08B | |
| -31.95x | 63.83x | -2.99x | 81.05x | -35.83x | -35.43x | -.--% | 42B | |
| 16.07x | 3.8x | 0.22x | 5.63x | 12.7x | 13.89x | 1.77% | 38.48B | |
| -23.53x | 1.07x | -1.05x | 3.18x | -8.69x | -6.87x | -.--% | 22.56B | |
| 17.14x | 3.22x | -5.29x | 4.23x | 11.29x | 11.92x | -.--% | 19.52B | |
| 27.25x | 2.52x | 0.71x | 5.35x | 14.82x | 18.45x | -.--% | 17.21B | |
| -479.05x | 13.13x | 7.56x | 27.63x | 651.54x | -555.7x | -.--% | 13.75B | |
| -13.42x | - | -0.05x | 168.49x | -26.27x | -13.08x | -.--% | 13.4B | |
| -176.93x | 21.46x | -2.3x | 41.95x | -170.33x | -150.5x | -.--% | 12.06B | |
| -56.86x | 21.09x | 1.03x | 12.83x | -54.38x | -48.82x | -.--% | 12.73B | |
| 16.24x | 4.26x | 0.36x | 4.52x | 11.22x | 12.62x | -.--% | 11.14B | |
| -20.72x | 17.2x | -0x | 21.3x | -32.38x | -20.19x | -.--% | 9.3B | |
| -18.33x | 8.7x | -0.4x | - | -18.86x | -18.22x | -.--% | 8.15B | |
| -9.83x | -15.01x | -0.48x | 86.67x | -12.03x | -11.73x | -.--% | 7.6B | |
| -16.53x | 12.91x | -0.22x | 126.27x | -19.21x | -18.71x | -.--% | 7.34B | |
| Average | -45.25x | 11.85x | -0.06x | 42.90x | 24.31x | -52.00x | 0.12% | 17.96B | |
| Weighted average by Cap. | -27.80x | 15.78x | -0.18x | 34.41x | 23.34x | -31.42x | 0.24% |
- Stock Market
- Equities
- VYNE Stock
- Sector VYNE Therapeutics Inc.
- Sector valuations
Select your edition
All financial news and data tailored to specific country editions
